Thermo Fisher Scientific Showcases Innovations in Proteomic Research at HUPO 2018
ORLANDO, Fla., Oct. 1, 2018 /PRNewswire/ -- HUPO 2018 – Demonstrating its commitment to advancing the performance of protein analysis, Thermo Fisher Scientific is showcasing its latest solutions and technologies at the 17th Human Proteome Organization (HUPO) World Congress (booth #401), September 30-October 3 at the Loews Royal Pacific, Orlando, Florida.
"We continue to partner with the research community to increase the depth of proteome analysis, adapt it for large-scale translational studies, and enable detailed structural analysis of proteins and complexes of interest," said Ken Miller, vice president, life sciences mass spectrometry marketing, Thermo Fisher Scientific. "We will showcase groundbreaking results from top labs in all of these areas in our workshops at HUPO 2018."
This year, Thermo Fisher will receive the HUPO Science and Technology Award in acknowledgement of the contribution made by Electron Transfer Dissociation (ETD) technology to proteome analysis. ETD is an alternative peptide fragmentation mode, which preserves phosphorylation and glycosylation modifications and contributes added structural information. It is currently available and widely utilized on the Thermo Scientific Orbitrap Tribrid portfolio of mass spectrometers.
Products on display at HUPO 2018
The new Thermo Scientific FAIMS Pro interface is a differential ion mobility technology that easily integrates with the Thermo Scientific Tribrid mass spectrometers designed to provide precision selectivity and enable extensive depth and quantitative accuracy of proteome measurements. Workflows including this interface are well suited for the key aspects of translational proteomics, specifically proteome coverage and profiling. Detailed study results will be shared at a FAIMS VIP Workshop at HUPO.
The Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap Mass Spectrometer provides new insights into the structure of proteins and complexes. With a greatly expanded mass range and an ability to trap and analyze intact proteins and complexes, this system allows for detailed analysis of protein structure, non-covalent binding interactions, and the subunit composition of large protein. The Q Exactive UHMR supports native mass spectrometry analysis and provides information that is highly complementary to cross-linking and hydrogen-deuterium exchange structure analysis workflows available on other Thermo Scientific mass spectrometers.
The newest version of Thermo Scientific Proteome Discoverer software provides comprehensive data processing capabilities for proteome analysis, many quantitative methods and protein structure studies, with extensive statistical and visualization tools. The new software features improved algorithms over previous versions, as well as an enhanced user interface, enabling scientists to extract the maximum possible data from their proteome studies. The most recent version of the software received a 2018 Industry Award from the European Proteomics Association in June of this year.
Other Activities at HUPO 2018
In cooperation with industry and company experts, Thermo Fisher is hosting a series of educational workshops during HUPO 2018 to highlight the latest scientific developments and applications. Workshops will focus on TMT multiplexing for quantitative proteome analysis, large-scale use of DIA methods in a global multi-site study, tools for protein structure analysis, and a new targeted protein analysis kit to help researchers profile cancer signaling pathways.
Among these workshops is Advancing Mass Spectrometry-based Large-cohort Proteomics for Precision Medicine: An International Cancer Moonshot Multi-Site Study (October 2, at 12:20–1:45 pm, in Room Java Sea) in which Dr. Thomas Conrads, Ph.D., associate director of scientific technologies, Inova Schar Cancer Institute, and Yue Xuan, senior global product marketing manager, precision medicine, Thermo Fisher Scientific, will present the results of a collaborative study involving 11 cancer research or clinical proteomics laboratories worldwide, including six Cancer Moonshot initiative laboratories.
"Bringing together scientists from across the globe, the International Cancer Moonshot Multi-Site Study accelerated progress and demonstrated the ability to harmonize high-throughput quantitative proteomics at new depths with exquisite analytical rigor," said Conrads.
Findings of the study demonstrate how Thermo Fisher's patented HRMS1-DIA label-free quantitative profiling workflow can facilitate high throughput and high inter- and intra-lab reproducibility when run in a 24/7 operation mode for an entire week. Designed for use with Thermo Scientific Orbitrap mass spectrometers, the HRMS1-DIA workflow creates the potential to leverage proteomic profiling as a guiding tool in translational large-cohort clinical studies.
For more information on Thermo Fisher's solutions and additional workshops at HUPO 2018, visit the Thermo Fisher website.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
Media Contact Information:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
[email protected]
or
Kat Steer
BioStrata
+44 (0) 1223 253787
[email protected]
SOURCE Thermo Fisher Scientific
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article